AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $12.8333.

ABCL has been the topic of several recent analyst reports. Cantor Fitzgerald upped their target price on AbCellera Biologics from $11.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Truist Financial upped their price objective on shares of AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen lowered shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Benchmark upgraded shares of AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research note on Tuesday, July 7th. Finally, Stifel Nicolaus boosted their target price on shares of AbCellera Biologics from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th.

AbCellera Biologics News Summary

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Positive Phase 2 results validate ABCL635: The experimental non-hormonal menopause treatment met its primary efficacy endpoints and significantly reduced the frequency and severity of moderate-to-severe hot flashes. The results are being viewed as a potential efficacy benchmark and represent AbCellera’s first meaningful pipeline win, improving investor confidence in its ability to develop proprietary medicines. Reuters article
• Positive Sentiment: Analyst sharply raises valuation target: Truist Financial upgraded its price target from $12 to $30 while maintaining a “Buy” rating, signaling substantial upside potential if ABCL635 advances successfully and the company’s pipeline gains commercial traction. Benzinga article
• Positive Sentiment: Bullish trading activity increased: Investors purchased 16,666 ABCL call options, approximately 151% above typical daily volume. While not a fundamental development, the activity indicates heightened speculative interest following the clinical announcement. Options trading article
• Neutral Sentiment: Investors are reassessing the company’s growth story: Coverage broadly agrees that the menopause data are strong, but the longer-term opportunity depends on whether ABCL635 can progress through later-stage testing and whether AbCellera can produce additional successful proprietary programs.
• Negative Sentiment: Proposed $200 million offering creates dilution risk: AbCellera launched an underwritten offering of common shares and pre-funded warrants. The capital would strengthen its balance sheet and fund development, but issuing new securities may dilute existing shareholders and pressure the stock in the near term. AbCellera offering announcement
• Negative Sentiment: Valuation and platform concerns remain: Some analysts contend that the post-announcement rally leaves ABCL approximately 33% overvalued and argue that the company’s broader antibody-discovery platform narrative is losing momentum. AbCellera also remains unprofitable, increasing sensitivity to execution and financing needs.

AbCellera Biologics Trading Up 4.5%

NASDAQ ABCL opened at $9.76 on Wednesday. The firm’s fifty day simple moving average is $6.35 and its two-hundred day simple moving average is $4.77. AbCellera Biologics has a 12-month low of $2.74 and a 12-month high of $10.29. The firm has a market capitalization of $2.99 billion, a P/E ratio of -18.07 and a beta of 1.20.

AbCellera Biologics (NASDAQ:ABCL) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). AbCellera Biologics had a negative return on equity of 17.49% and a negative net margin of 248.83%.The business had revenue of $4.05 million for the quarter, compared to analyst estimates of $7.85 million. As a group, sell-side analysts predict that AbCellera Biologics will post -0.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On AbCellera Biologics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of AbCellera Biologics during the fourth quarter valued at $26,938,000. Two Sigma Investments LP raised its stake in AbCellera Biologics by 25.9% in the 3rd quarter. Two Sigma Investments LP now owns 5,175,142 shares of the company’s stock worth $26,031,000 after acquiring an additional 1,064,290 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in AbCellera Biologics by 1,636.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,344,485 shares of the company’s stock worth $14,858,000 after acquiring an additional 4,094,268 shares during the period. BlackRock Inc. acquired a new stake in AbCellera Biologics during the 2nd quarter worth about $29,872,000. Finally, Bank of America Corp DE grew its stake in AbCellera Biologics by 13.9% during the 1st quarter. Bank of America Corp DE now owns 2,999,936 shares of the company’s stock valued at $10,470,000 after purchasing an additional 367,064 shares during the last quarter. 61.42% of the stock is currently owned by institutional investors and hedge funds.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.